DelMar Pharmaceuticals Inc. received a notice of allowance from the U.S. Patent and Trademark Office for its patent application involving VAL-083, a potential brain cancer treatment.
VAL-083 is under preparation for a phase 3 clinical trial in the U.S. as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer.
The patent has also been granted in Australia and is being prosecuted in other international jurisdictions as part of more than 100 patent filings from 13 patent families representing claims covering VAL-083 until 2036.
DelMar expects the U.S. patent to be issued in early 2017.